Figure 3.

Licochalcone A suppresses EGFR signalling. A, B, The binding modes of licochalcone A with WT and mutant EGFRs. Cartoon representation of licochalcone A binding pocket in EGFR (A). Different binding modes of licochalcone A with 4 types of EGFR (B). The ligands were shown in the sticks, whereas proteins were depicted in cartoon representation with key residues indicated as grey sticks. Hydrogen bonds are shown as red dashed lines, and the cation‐π interaction is shown as yellow dashed line. Besides, the relating residues or ligands were well labelled. C, Licochalcone A inhibits EGFR signalling in NSCLC cells. The NSCLC cells were treated with licochalcone A and osimertinib, and whole‐cell extracts (WCE) were subjected to IB analysis. D, Ba/F3 cells stable cells were pre‐treated with licochalcone A or osimertinib for 2 h and then treated with EGF for 15 min. WCE was collected and subjected to IB analysis